Gys1 maze therapeutics
WebFeb 17, 2024 · The latest longevity updates from our investment news desk. Maze completes Phase 1 trial. Precision medicine company Maze Therapeutics announced the completion of its first-in-human clinical trial of MZE001 in healthy volunteers. MZE001 is an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting … WebFeb 17, 2024 · MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for the …
Gys1 maze therapeutics
Did you know?
WebFeb 21, 2024 · Phase. Healthy. Drug: MZE001 Drug: Placebo. Phase 1. Detailed Description: Phase 1 study is designed to evaluate the safety, tolerability, … WebJan 31, 2024 · Maze Therapeutics is a biopharmaceutical company applying advanced data science methods in tandem with a robust suite of research and development capabilities to advance a pipeline of novel precision medicines for patients with genetically defined diseases.
WebFeb 18, 2024 · Maze Therapeutics has commenced participant dosing in its Phase I trial of MZE001 in a bid to advance its Pompe disease program. MZE001 is an oral glycogen … WebJan 31, 2024 · SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced …
WebMar 22, 2024 · MZE001, a selective inhibitor of glycogen synthase 1 in muscle, is being developed to address this therapeutic gap. Maze has developed a novel biomarker, peripheral blood mononuclear cell (PBMC)...
WebJul 5, 2024 · Maze Therapeutics. Aug 2024 - Present1 year 9 months. South San Francisco, California, United States.
WebDec 15, 2024 · MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address Pompe disease by limiting disease-causing glycogen buildup, is being evaluated for ... December 15, 2024--Maze Therapeutics ... toilets rear dischargeWebMar 22, 2024 · GYS1 is an enzyme responsible for glycogen production. MZE001 is currently being evaluated as a potential oral treatment for patients with Pompe disease, … people sterlingWebFeb 10, 2024 · Taken together, the preclinical data support the potential for a GYS1 inhibitor, such as MZE001, as a treatment for Pompe disease. Based on these findings, … toilets rebateWebFeb 27, 2024 · SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced positive results from the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.MZE001, an oral glycogen synthase (GYS1) inhibitor that aims to address … toilets reeceWebFeb 10, 2024 · Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new preclinical data supporting the advancement of MZE001, which aims to address Pompe disease by reducing pathologic glycogen accumulation through the inhibition of muscle glycogen synthase (GYS1). peoples theatre in markhamWebMar 23, 2024 · Maze Therapeutics, which came out of stealth mode more than two years ago with $191 million in funding to translate genetic insights into new precision medicines, has revealed its first three lead therapeutic candidates … toilets redWebGlycogen synthase 1 “is the rate limiting enzyme in muscle glycogen biosynthesis” 72 and its genetic ablation in Pompe mouse models lowered the amount of glycogen accumulation and muscle pathology. 72 A group of scientists from Maze Therapeutics in the USA developed an orally bioavailable small molecule (MZE001) which inhibits this enzyme ... peoples theatre markham